• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Moderna regains RSV vaccine programme from Merck pharmaceutical-technology
    October 12, 2020
    Merck (MSD) has returned all rights to a respiratory syncytial virus (RSV) vaccine, mRNA-1172, to Moderna, including rights to develop vaccines against the virus for adults.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service